In the imiquimod (IMQ)-induced psoriasis model, IMQ acts as an agonist of TRPA1 and activates CD4+ T cells through TRPA1, which in turn reduces the release of neuropeptides from the nerve endings, attenuates dendritic cell activation, reduces the release of IL-12 and IL-23, and reduces T helper type l (Th1) or T helper typel7 (Th17) T cells and skin inflammation (Kemény et al., 2018; Wei et al., 2020). Here, TRPA1 is linked to psoriasis.